The Patent Finder

Simcere Zaiming Pharmaceutical Co., Ltd.

Also on record
Records under this name other than the patents Simcere Zaiming Pharmaceutical Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.

Back to Simcere Zaiming Pharmaceutical Co., Ltd.

PatentTitleStatus Expires Confidence
18/264,486Human CD33 Antibody and Use Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/266,125Anti-Egfr Nanobody and Use Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/266,393GPC3 Antibody and Application Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/267,518CD5 Antibody and Use Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/267,561HER2 Antibody and Application Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/272,539Anti-Human CD22 Monoclonal Antibodies and Use Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/275,529Monoclonal Antibody for Specifically Recognizing GLYPICAN-3, and Application Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/275,901Humanized GPC3 Antibody and Application Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/554,426Ubiquitin-Specific Protease 1 (USP1) Inhibitor
Abandoned
Abandoned Aug 5, 2026
AbandonedAbandoned Aug 5, 2026
18/577,325CD19 Antibody and Application Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
10 of 26 records shown.
Pro members see all 26.
Pro members: see all 26 records
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited